Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology
Avoids 4-1BB/OX-40 Toxicity Issues
Executive Summary
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Roche shores up oncology; Janssen’s multiple myeloma strategy; gene therapy safety; a new PD-1 inhibitor moves forward in the US; and herd immunity and COVID.
Coronavirus Update: Sotrovimab Filed For EUA In Japan
GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private.